Comparator Issues Thwart Cosentyx Benefit Assessment In Germany
A key trial comparing Novartis’s Cosentyx with etanercept did not allow a fair comparison of the two products because it failed to ensure all patients received adequate medical care, said IQWiG, Germany’s HTA body.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.